/SCYX
SCYX Stock - SCYNEXIS, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$0.63-0.56%
$0.00 (-0.56%) • Dec 19
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.9
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.65
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.69
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SCYX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.62 – $0.63
TARGET (TP)$0.72
STOP LOSS$0.58
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.36
52W High$1.49
52W Low$0.56
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.75M | $140.14M | $5.09M | $13.16M | N/A |
| Gross Profit | $3.75M | $124.52M | $4.46M | $12.85M | $-303,000 |
| Gross Margin | 100.0% | 88.9% | 87.7% | 97.6% | N/A |
| Operating Income | $-37,117,000 | $72.67M | $-85,757,000 | $-60,838,000 | $-51,149,000 |
| Net Income | $-21,288,000 | $67.04M | $-62,809,000 | $-32,866,000 | $-55,185,000 |
| Net Margin | -568.3% | 47.8% | -1233.7% | -249.7% | N/A |
| EPS | $-0.44 | $1.40 | $-1.47 | $-1.25 | $-5.15 |
Company Overview
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SCYXBeat Rate
72%
Last 18 quarters
Avg Surprise
+3.7%
EPS vs Estimate
Beats / Misses
13/5
Last 12 quarters
Latest EPS
$-0.17
Q4 2025
EPS Surprise History
Q1 24
-225.8%
$-0.39vs$0.31
Q2 24
+16.7%
$-0.15vs$-0.18
Q3 24
-57.9%
$-0.30vs$-0.19
Q4 24
+70.0%
$-0.06vs$-0.20
Q1 25
+59.1%
$-0.09vs$-0.22
Q2 25
+26.1%
$-0.17vs$-0.23
Q3 25
+39.1%
$-0.14vs$-0.23
Q4 25
+19.0%
$-0.17vs$-0.21
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 11, 2026 | $0.29 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.21 | $-0.17 | +19.0% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.23 | $-0.14 | +39.1% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.23 | $-0.17 | +26.1% | ✓ BEAT |
Q1 2025 | Mar 12, 2025 | $-0.22 | $-0.09 | +59.1% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.20 | $-0.06 | +70.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.19 | $-0.30 | -57.9% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.18 | $-0.15 | +16.7% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $0.31 | $-0.39 | -225.8% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $0.29 | $-0.04 | -113.8% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $1.55 | $2.46 | +58.7% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.28 | $-0.25 | +10.7% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.50 | $-0.29 | +42.0% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.51 | $-0.62 | -21.6% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.57 | $-0.53 | +7.0% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.74 | $-0.51 | +31.1% | ✓ BEAT |
Q1 2022 | Mar 29, 2022 | $-0.71 | $-1.05 | -47.9% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.79 | $-0.06 | +92.4% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.58 | $-0.22 | +62.1% | ✓ BEAT |
Latest News
SCYNEXIS Completes Transfer Of BREXAFEMME New Drug Application To GSK
📈 PositiveBenzinga•Nov 19, 2025, 12:09 PM•Also:
SCYNEXIS Secures 5-Year $7M Annual Federal Grant To Advance Next-Generation Antifungal Therapies
📈 PositiveBenzinga•Nov 17, 2025, 03:17 PM
SCYNEXIS Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $334.000K Beat $147.667K Estimate
📈 PositiveBenzinga•Nov 5, 2025, 10:04 PM
Guggenheim Maintains Buy on SCYNEXIS, Lowers Price Target to $3
➖ NeutralBenzinga•Oct 28, 2025, 12:41 PM
Trading Halt: Halt status updated at 8:20:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 15, 2025, 12:20 PM
SCYNEXIS To Receive $22M From GlaxoSmithKline To Resolve Dispute Over Restarting The Phase 3 Mario Study For Invasive Candidiasis.
➖ NeutralBenzinga•Oct 15, 2025, 12:08 PM•Also:
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 15, 2025, 11:55 AM
SCYNEXIS Reports Results From Phase 1 Study Of SCY-247, Second-Gen Triterpenoid Antifungal Under Development For Treatment And Prevention Of Invasive Fungal Infections
➖ NeutralBenzinga•Sep 30, 2025, 12:07 PM
SCYNEXIS To Present At 12th Congress on Trends in Medical Mycology Sept. 19-22
➖ NeutralBenzinga•Sep 4, 2025, 12:38 PM
Frequently Asked Questions about SCYX
What is SCYX's current stock price?
SCYNEXIS, Inc. (SCYX) is currently trading at $0.63 per share. The stock has moved -0.56% today.
What is the analyst price target for SCYX?
No analyst price targets are currently available for this stock.
What sector is SCYNEXIS, Inc. in?
SCYNEXIS, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is SCYX's market cap?
SCYNEXIS, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does SCYX pay dividends?
No, SCYNEXIS, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLGN
CollPlant Biotechnologies Ltd.
$1.52
Mkt Cap: $0.0B
COSM
Cosmos Health Inc.
$0.49
Mkt Cap: $0.0B
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$7.11
Mkt Cap: $0.0B
KLTO
Klotho Neurosciences, Inc.
$0.39
Mkt Cap: $0.0B
NRSN
NeuroSense Therapeutics Ltd.
$0.81
Mkt Cap: $0.0B
NRXS
NeurAxis, Inc.
$3.22
Mkt Cap: $0.0B
NXL
Nexalin Technology, Inc.
$0.83
Mkt Cap: $0.0B
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
Mkt Cap: $0.0B
TLPH
Talphera, Inc.
$1.10
Mkt Cap: $0.0B
XCUR
Exicure, Inc.
$5.92
Mkt Cap: $0.0B
Explore stocks similar to SCYX for comparison